MedTrace Logo

Early Diagnosis of Atrial Fibrillation in the Wait-Time Prior to Seeing a Cardiologist

NCT04302311 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2024-02-28

No results posted yet for this study

Summary

A randomized patient-oriented trial to investigate whether continual symptomatic use of the Kardia Mobile monitoring device is a superior strategy for diagnosing Atrial Fibrillation (AF) in comparison to normal ambulatory monitoring with a 24-hour Holter monitor. Patients with referrals to an Electrophysiologist, symptoms of AF but no documentation of AF, and with at least one stroke risk factor based on the CHADS2 scoring system are randomized 1:1 to Kardia Mobile monitoring versus Holter monitoring alone.

Conditions

Interventions

DIAGNOSTIC_TEST

Holter monitoring

Use of smart device application and technologies to assess for arrhythmias

DIAGNOSTIC_TEST

Kardia/AliveCor monitoring

Kardia/AliveCor monitoring

Sponsors & Collaborators

  • Victoria Cardiac Arrhythmia Trials

    lead OTHER

Principal Investigators

  • Markus Sikkel, MD · Victoria Cardiac Arrhythmia Trials Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2022-10-21
Completion
2024-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04302311 on ClinicalTrials.gov